Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marco Capobianco

Showing results (31-40 of 76) with videos related to

Pageof 8
Sort By:
Multiple Sclerosis (Houndmills, Basingstoke, England)|February 21, 2015
Natalizumab discontinuation in patients with multiple sclerosis: Profiling risk and benefits at therapeutic crossroadsLuca Prosperini, Pietro Annovazzi, Marco Capobianco, et al.
Journal of the Neurological Sciences|June 2, 2017
Is maraviroc useful in multiple sclerosis patients with natalizumab-related progressive multifocal leukoencephalopathy?Cristina Scarpazza, Luca Prosperini, Chiara R Mancinelli, et al.
Journal of Neurology|October 17, 2025
Efficacy and safety of ublituximab for relapsing multiple sclerosis patients: current evidence and expert opinionPaolo Preziosa, Vincenzo Brescia Morra, Marco Capobianco, et al.
Pathogens (Basel, Switzerland)|June 26, 2024
Cytomegalovirus, Epstein-Barr Virus, Herpes Simplex Virus, and Varicella Zoster Virus Infection Dynamics in People with Multiple Sclerosis from Northern ItalyPeter A Maple, Radu Tanasescu, Cris S Constantinescu, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|April 23, 2020
Effectiveness of fingolimod in real-world relapsing-remitting multiple sclerosis Italian patients: the GENIUS studyGiancarlo Comi, Carlo Pozzilli, Vincenzo Brescia Morra, et al.
Journal of Neuroimmunology|October 24, 2007
Anti-interferon-beta neutralising activity is not entirely mediated by antibodiesFrancesca Gilli, Fabiana Marnetto, Marzia Caldano, et al.
Plos One|February 4, 2010
Learning from nature: pregnancy changes the expression of inflammation-related genes in patients with multiple sclerosisFrancesca Gilli, Raija L P Lindberg, Paola Valentino, et al.
Multiple Sclerosis and Related Disorders|August 7, 2022
Fetal and post-natal growth in infants of mothers with multiple sclerosis: A case-control studLuca Marozio, Paola Cavalla, Stefano Sottemano, et al.
Journal of Neurology|November 20, 2023
COVID-19 outbreak in Italy: an opportunity to evaluate extended interval dosing of ocrelizumab in MS patientsAlvino Bisecco, Federica Matrone, Marco Capobianco, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|April 24, 2009
Long-term results of immunomodulatory treatment in children and adolescents with multiple sclerosis: the Italian experienceAngelo Ghezzi, Maria Pia Amato, Pietro Annovazzi, et al.
Pageof 8

Showing results (31-40 of 76) with videos related to

Sort By:
Pageof 8
Multiple Sclerosis (Houndmills, Basingstoke, England)|February 21, 2015
Natalizumab discontinuation in patients with multiple sclerosis: Profiling risk and benefits at therapeutic crossroadsLuca Prosperini, Pietro Annovazzi, Marco Capobianco, et al.
Journal of the Neurological Sciences|June 2, 2017
Is maraviroc useful in multiple sclerosis patients with natalizumab-related progressive multifocal leukoencephalopathy?Cristina Scarpazza, Luca Prosperini, Chiara R Mancinelli, et al.
Journal of Neurology|October 17, 2025
Efficacy and safety of ublituximab for relapsing multiple sclerosis patients: current evidence and expert opinionPaolo Preziosa, Vincenzo Brescia Morra, Marco Capobianco, et al.
Pathogens (Basel, Switzerland)|June 26, 2024
Cytomegalovirus, Epstein-Barr Virus, Herpes Simplex Virus, and Varicella Zoster Virus Infection Dynamics in People with Multiple Sclerosis from Northern ItalyPeter A Maple, Radu Tanasescu, Cris S Constantinescu, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|April 23, 2020
Effectiveness of fingolimod in real-world relapsing-remitting multiple sclerosis Italian patients: the GENIUS studyGiancarlo Comi, Carlo Pozzilli, Vincenzo Brescia Morra, et al.
Journal of Neuroimmunology|October 24, 2007
Anti-interferon-beta neutralising activity is not entirely mediated by antibodiesFrancesca Gilli, Fabiana Marnetto, Marzia Caldano, et al.
Plos One|February 4, 2010
Learning from nature: pregnancy changes the expression of inflammation-related genes in patients with multiple sclerosisFrancesca Gilli, Raija L P Lindberg, Paola Valentino, et al.
Multiple Sclerosis and Related Disorders|August 7, 2022
Fetal and post-natal growth in infants of mothers with multiple sclerosis: A case-control studLuca Marozio, Paola Cavalla, Stefano Sottemano, et al.
Journal of Neurology|November 20, 2023
COVID-19 outbreak in Italy: an opportunity to evaluate extended interval dosing of ocrelizumab in MS patientsAlvino Bisecco, Federica Matrone, Marco Capobianco, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|April 24, 2009
Long-term results of immunomodulatory treatment in children and adolescents with multiple sclerosis: the Italian experienceAngelo Ghezzi, Maria Pia Amato, Pietro Annovazzi, et al.
Pageof 8